US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, on Thursday announced US Food and Drug Administration approval of BRAVECTO QUANTUM (fluralaner for extended-release injectable suspension), a 12-month injectable treatment for flea and tick infestations in dogs.

The Merck Animal Health product is expected to be available at veterinary clinics and hospitals across the United States by August 2025.

BRAVECTO QUANTUM provides year-long protection with a single dose and is the first systemic parasiticide of its kind to offer such duration. It targets and prevents infestations from adult fleas and multiple tick species, including black-legged, American dog, and brown dog ticks for 12 months, and lone star ticks for eight months.

Previously approved in Australia and New Zealand in 2023 and the European Union in 2024, BRAVECTO QUANTUM is now authorised in over 50 countries globally.

The product's patented fluralaner formulation is designed to maintain effective levels in dogs for up to one year, addressing a critical need for continuous, long-term parasite control.

With this approval, Merck Animal Health expands its BRAVECTO portfolio and reinforces its presence in the global companion animal health market.